- Home
- BPMC vs CZR Comparison
BPMC vs CZR Comparison
Compare BPMC & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- CZR
- Stock Information
- Founded
- BPMC 2008
- CZR 1937
- Country
- BPMC United States
- CZR United States
- Employees
- BPMC N/A
- CZR N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- CZR Hotels/Resorts
- Sector
- BPMC Health Care
- CZR Consumer Discretionary
- Exchange
- BPMC Nasdaq
- CZR Nasdaq
- Market Cap
- BPMC 5.8B
- CZR 5.4B
- IPO Year
- BPMC 2015
- CZR 1989
- Fundamental
- Price
- BPMC $128.35
- CZR $29.71
- Analyst Decision
- BPMC Buy
- CZR Strong Buy
- Analyst Count
- BPMC 20
- CZR 13
- Target Price
- BPMC $127.82
- CZR $44.00
- AVG Volume (30 Days)
- BPMC 3.6M
- CZR 5.6M
- Earning Date
- BPMC 07-31-2025
- CZR 07-29-2025
- Dividend Yield
- BPMC N/A
- CZR N/A
- EPS Growth
- BPMC N/A
- CZR N/A
- EPS
- BPMC N/A
- CZR N/A
- Revenue
- BPMC $562,121,000.00
- CZR $11,297,000,000.00
- Revenue This Year
- BPMC $44.46
- CZR $3.33
- Revenue Next Year
- BPMC $32.78
- CZR $2.50
- P/E Ratio
- BPMC N/A
- CZR N/A
- Revenue Growth
- BPMC 99.19
- CZR N/A
- 52 Week Low
- BPMC $73.04
- CZR $21.40
- 52 Week High
- BPMC $128.52
- CZR $45.93
- Technical
- Relative Strength Index (RSI)
- BPMC 74.59
- CZR 60.09
- Support Level
- BPMC $128.06
- CZR $28.09
- Resistance Level
- BPMC $128.52
- CZR $30.29
- Average True Range (ATR)
- BPMC 0.28
- CZR 1.00
- MACD
- BPMC -1.18
- CZR 0.25
- Stochastic Oscillator
- BPMC 74.44
- CZR 88.16
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across the Las Vegas (49% of 2024 EBITDAR before corporate expenses) and regional (46%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2024. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.